Nykode Therapeutics AS Statistics
Total Valuation
VACBF has a market cap or net worth of 57.20 million. The enterprise value is -51.59 million.
| Market Cap | 57.20M |
| Enterprise Value | -51.59M |
Important Dates
The last earnings date was Wednesday, May 28, 2025.
| Earnings Date | May 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 326.55M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.17% |
| Shares Change (QoQ) | -3.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 146.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.91 |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1.08 |
Financial Position
The company has a current ratio of 16.92, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.92 |
| Quick Ratio | 16.92 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -244.06 |
Financial Efficiency
Return on equity (ROE) is -17.30% and return on invested capital (ROIC) is -16.72%.
| Return on Equity (ROE) | -17.30% |
| Return on Assets (ROA) | -14.87% |
| Return on Invested Capital (ROIC) | -16.72% |
| Return on Capital Employed (ROCE) | -28.72% |
| Revenue Per Employee | 110,387 |
| Profits Per Employee | -337,613 |
| Employee Count | 136 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.36% in the last 52 weeks. The beta is 1.17, so VACBF's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -86.36% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 14.12 |
| Average Volume (20 Days) | 2,777 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, VACBF had revenue of 8.28 million and -25.32 million in losses. Loss per share was -0.08.
| Revenue | 8.28M |
| Gross Profit | 8.28M |
| Operating Income | -40.27M |
| Pretax Income | -32.56M |
| Net Income | -25.32M |
| EBITDA | -39.53M |
| EBIT | -40.27M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 106.23 million in cash and 3.28 million in debt, giving a net cash position of 102.96 million.
| Cash & Cash Equivalents | 106.23M |
| Total Debt | 3.28M |
| Net Cash | 102.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 133.95M |
| Book Value Per Share | 0.41 |
| Working Capital | 102.19M |
Cash Flow
In the last 12 months, operating cash flow was -47.64 million and capital expenditures -89,000, giving a free cash flow of -47.72 million.
| Operating Cash Flow | -47.64M |
| Capital Expenditures | -89,000 |
| Free Cash Flow | -47.72M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -486.41% |
| Pretax Margin | -393.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VACBF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.17% |
| Shareholder Yield | n/a |
| Earnings Yield | -44.26% |
| FCF Yield | -83.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VACBF has an Altman Z-Score of 10.76 and a Piotroski F-Score of 1.
| Altman Z-Score | 10.76 |
| Piotroski F-Score | 1 |